bone metastases
Oncology · 2024–2025
2decisions
1medicine
2carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| denosumab Treatment of giant cell tumour of bone (in adults and skeletally mature adolescents that is recurrent, unresectable, or resectable but associated with severe… | Mar 2025 | Recommended | 3 individuals |
| denosumab Jubbonti (60 mg): treatment of osteoporosis (BMD T-score of -2.5 or less) in patients over 70 years old, and established osteoporosis (patients who have… | Nov 2024 | Recommended | input received Medical Oncology Group · Rare Cancers Australia |
Who spoke
Medical Oncology Group · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.